Poolbeg Pharma, a London-based startup, is set to trial a drug at six NHS hospitals that aims to prevent a life-threatening side effect associated with cancer immunotherapy. The oral drug, known as POLB, is designed to stop cytokine storm, a severe reaction that can occur in patients undergoing cancer treatment. According to the company, the trial marks a significant step in its efforts to develop treatments for patients undergoing immunotherapy. Poolbeg Pharma is also working on a GLP-1 weight loss pill, expanding its portfolio of potential treatments. The company's focus on developing therapies for patients with cancer and other conditions highlights the growing importance of targeted treatments in the fight against disease.
The trial's outcome may have implications for the treatment of cancer patients and the management of side effects associated with immunotherapy. Further information on the trial's specifics, such as the number of participants and expected duration, is not available in the provided source.